Document is current
Any future updates will be listed below
-
Authors
Strikwerda, Marije A https://orcid.org/0000-0002-3976-0694
Hoeijmakers, Lotte L https://orcid.org/0009-0003-8431-7557
Veenstra, Sophie P G R
Van Den Eertwegh, Alfons J M
Labots, Mariette https://orcid.org/0000-0002-7095-1771
Blank, Christian U
Mom, Constantijne H https://orcid.org/0000-0003-2838-2031
De Gruijl, Tanja D
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03698019 at ClinicalTrials.govnct04949113 at ClinicalTrials.govDocuments that mention this clinical trial
Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?
https://doi.org/10.1136/jitc-2025-014324
nct03553836 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: <i>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</i>
https://doi.org/10.1136/jitc-2023-006947add1
Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?
https://doi.org/10.1136/jitc-2025-014324
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba9584
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba2
nct04099251 at ClinicalTrials.govDocuments that mention this clinical trial
Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba9505
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial
https://doi.org/10.1136/jitc-2023-007501
Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?
https://doi.org/10.1136/jitc-2025-014324
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study
https://doi.org/10.1200/jco.23.02355
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
https://doi.org/10.1136/jitc-2021-003272
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
https://doi.org/10.1136/jitc-2021-002920
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
nct01042379 at ClinicalTrials.govDocuments that mention this clinical trial
Addendum 1: <i>Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0</i>
https://doi.org/10.1136/jitc-2023-006947add1
Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?
https://doi.org/10.1136/jitc-2025-014324
Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).
https://doi.org/10.1200/jco.2023.41.16_suppl.9504
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence
https://doi.org/10.1136/jitc-2021-003272
Trends in clinical development of pediatric cancer for PD-1 and PD-L1 inhibitors: an analysis of ClinicalTrials.gov
https://doi.org/10.1136/jitc-2021-002920
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
https://doi.org/10.1136/jitc-2023-006947
nct04185311 at ClinicalTrials.govDocuments that mention this clinical trial
Is the NCI MATCH trial a match for gynecologic oncology?
https://doi.org/10.1016/j.ygyno.2015.11.003
Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study – a multicentre prospective observational cohort study
https://doi.org/10.1136/bmjopen-2022-061334
Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.
https://doi.org/10.1200/jco.2024.42.16_suppl.582
Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?
https://doi.org/10.1136/jitc-2025-014324
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
https://doi.org/10.1200/po-24-00776
Use of PROMIS to capture patient reported outcomes over time for patients on I-SPY2.
https://doi.org/10.1200/jco.2023.41.16_suppl.611
Pathological complete response to predict long term outcomes in the I-SPY2 TRIAL.
https://doi.org/10.1200/jco.2024.42.16_suppl.597
Study designs for clinical trials applied to personalised medicine: a scoping review
https://doi.org/10.1136/bmjopen-2021-052926
Human and financial consequences of herding in oncology drug development: clinical trials of TIGIT inhibitors
https://doi.org/10.1136/bmjonc-2025-001037
Current Challenges in Cancer Treatment
https://doi.org/10.1016/j.clinthera.2016.03.026
Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo
https://doi.org/10.1016/j.ygyno.2014.08.006
Correlation of HER2 low status in I-SPY2 with molecular subtype, response, and survival.
https://doi.org/10.1200/jco.2023.41.16_suppl.514
Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba612
Targeting immune checkpoints in breast cancer: an update of early results
https://doi.org/10.1136/esmoopen-2017-000255
How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies
https://doi.org/10.1136/esmoopen-2018-000357
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba509
Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.
https://doi.org/10.1200/jco.2023.41.17_suppl.lba520
Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.594
Association of germline polygenic risk for thyroid autoimmunity with overall survival in the I-SPY2 Trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.10600
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
https://doi.org/10.1007/s10549-024-07555-9
Lifting the innate immune barriers to antitumor immunity
https://doi.org/10.1136/jitc-2020-000695
Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
https://doi.org/10.1200/jco.2024.42.23_suppl.1
A review of phase II trial designs for initial marker validation
https://doi.org/10.1016/j.cct.2013.05.001
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
https://doi.org/10.1136/jitc-2020-002179
Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.
https://doi.org/10.1200/jco.2024.42.16_suppl.584
Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).
https://doi.org/10.1200/jco.2023.41.16_suppl.102
Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo
https://doi.org/10.1016/j.ygyno.2015.08.002
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.
https://doi.org/10.1200/jco.2024.42.17_suppl.lba501
I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
https://doi.org/10.1200/jco.2024.42.16_suppl.601
Evaluation of symptom severity, tolerability, and physical function in the I-SPY2 trial.
https://doi.org/10.1200/op.2023.19.11_suppl.369
nct06736379 at ClinicalTrials.govDocuments that mention this clinical trial
Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?
https://doi.org/10.1136/jitc-2025-014324
nct06095674 at ClinicalTrials.govDocuments that mention this clinical trial
Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?
https://doi.org/10.1136/jitc-2025-014324
Documents that mention this clinical trial
Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity?
https://doi.org/10.1136/jitc-2025-014324
- License Information
